OBJECTIVE: To estimate the incidence and risk factors for gastrointestinal (GI) perforation among patients with rheumatoid arthritis (RA). METHODS: Claims from employer health insurance plans were used to identify RA patients and those hospitalized for upper or lower GI perforation. GI perforation cases were identified using both a sensitive and a specific definition. A Cox model using fixed and time-varying covariates was used to evaluate the risk of GI perforation. RESULTS: Among 143,433 RA patients, and using a maximally sensitive GI perforation definition, 696 hospitalizations with perforation were identified. The rate of perforation was 1.70 per 1,000 person years (PYs; 95% confidence interval [95% CI] 1.58-1.83), and most perforations (83%) occurred in the lower GI tract. The rate of perforation was lower when a more specific GI perforation definition was used (0.87; 95% CI 0.78-0.96 per 1,000 PYs). Age and diverticulitis were among the strongest risk factors for perforation (diverticulitis hazard ratio [HR] 14.5 [95% CI 11.8-17.7] for the more sensitive definition, HR 3.9 [95% CI 2.5-5.9] for the more specific definition). Among various RA medication groups and compared to methotrexate, the risk of GI perforation was highest among patients with exposure to nonsteroidal antiinflammatory drugs (NSAIDs), concomitant nonbiologic disease-modifying antirheumatic drugs, and glucocorticoids. Biologic agents without glucocorticoid exposure were not a risk factor for perforation. CONCLUSION: GI perforation is a rare but serious condition that affects patients with RA, most frequently in the lower GI tract. Clinicians should be aware of risk factors for GI perforation when managing RA patients, including age, history of diverticulitis, and use of glucocorticoids or NSAIDs.
OBJECTIVE: To estimate the incidence and risk factors for gastrointestinal (GI) perforation among patients with rheumatoid arthritis (RA). METHODS: Claims from employer health insurance plans were used to identify RApatients and those hospitalized for upper or lower GI perforation. GI perforation cases were identified using both a sensitive and a specific definition. A Cox model using fixed and time-varying covariates was used to evaluate the risk of GI perforation. RESULTS: Among 143,433 RApatients, and using a maximally sensitive GI perforation definition, 696 hospitalizations with perforation were identified. The rate of perforation was 1.70 per 1,000 person years (PYs; 95% confidence interval [95% CI] 1.58-1.83), and most perforations (83%) occurred in the lower GI tract. The rate of perforation was lower when a more specific GI perforation definition was used (0.87; 95% CI 0.78-0.96 per 1,000 PYs). Age and diverticulitis were among the strongest risk factors for perforation (diverticulitis hazard ratio [HR] 14.5 [95% CI 11.8-17.7] for the more sensitive definition, HR 3.9 [95% CI 2.5-5.9] for the more specific definition). Among various RA medication groups and compared to methotrexate, the risk of GI perforation was highest among patients with exposure to nonsteroidal antiinflammatory drugs (NSAIDs), concomitant nonbiologic disease-modifying antirheumatic drugs, and glucocorticoids. Biologic agents without glucocorticoid exposure were not a risk factor for perforation. CONCLUSION: GI perforation is a rare but serious condition that affects patients with RA, most frequently in the lower GI tract. Clinicians should be aware of risk factors for GI perforation when managing RApatients, including age, history of diverticulitis, and use of glucocorticoids or NSAIDs.
Authors: A Lanas; L A García-Rodríguez; M Polo-Tomás; M Ponce; E Quintero; M A Perez-Aisa; J P Gisbert; L Bujanda; M Castro; M Muñoz; M D Del-Pino; S Garcia; X Calvet Journal: Aliment Pharmacol Ther Date: 2011-01-05 Impact factor: 8.171
Authors: Lisa L Strate; Yan L Liu; Edward S Huang; Edward L Giovannucci; Andrew T Chan Journal: Gastroenterology Date: 2011-02-12 Impact factor: 22.682
Authors: Francis K L Chan; Angel Lanas; James Scheiman; Manuela F Berger; Ha Nguyen; Jay L Goldstein Journal: Lancet Date: 2010-06-16 Impact factor: 79.321
Authors: Francis K L Chan; Byron Cryer; Jay L Goldstein; Angel Lanas; David A Peura; James M Scheiman; Lee S Simon; Gurkirpal Singh; Martin J Stillman; Charles M Wilcox; Manuela F Berger; Aurora Breazna; William Dodge Journal: J Rheumatol Date: 2009-11-02 Impact factor: 4.666
Authors: Sebastian Straube; Martin R Tramèr; R Andrew Moore; Sheena Derry; Henry J McQuay Journal: BMC Gastroenterol Date: 2009-06-05 Impact factor: 3.067
Authors: Gerd R Burmester; Peter Nash; Bruce E Sands; Kim Papp; Lori Stockert; Thomas V Jones; Huaming Tan; Ann Madsen; Hernan Valdez; Stanley B Cohen Journal: RMD Open Date: 2021-05
Authors: Josef S Smolen; Monika M Schoels; Norihiro Nishimoto; Ferdinand C Breedveld; Gerd R Burmester; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K Kvien; Miho Murakami; Neil Betteridge; Clifton O Bingham; Vivian Bykerk; Ernest H Choy; Bernard Combe; Maurizio Cutolo; Winfried Graninger; Angel Lanas; Emilio Martin-Mola; Carlomaurizio Montecucco; Mikkel Ostergaard; Karel Pavelka; Andrea Rubbert-Roth; Naveed Sattar; Marieke Scholte-Voshaar; Yoshiya Tanaka; Michael Trauner; Gabriele Valentini; Kevin L Winthrop; Maarten de Wit; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2012-11-21 Impact factor: 19.103
Authors: Stanley B Cohen; Yoshiya Tanaka; Xavier Mariette; Jeffrey R Curtis; Eun Bong Lee; Peter Nash; Kevin L Winthrop; Christina Charles-Schoeman; Krishan Thirunavukkarasu; Ryan DeMasi; Jamie Geier; Kenneth Kwok; Lisy Wang; Richard Riese; Jürgen Wollenhaupt Journal: Ann Rheum Dis Date: 2017-01-31 Impact factor: 19.103